Search research articles
Contact Us
Filters
Showing results (151-160 of 185) with videos related to
Page
of 19
Sort By:
Progres En Urologie : Journal De L'Association Francaise D'Urologie Et De La Societe Francaise D'Urologie
|
February 4, 2014
[CCAFU Recommendations 2013: Testicular germ cell cancer]
X Durand, J Rigaud, C Avancès, et al.
British Journal of Cancer
|
August 17, 2000
Prognostic factors for tumour response, progression-free survival and toxicity in metastatic colorectal cancer patients given irinotecan (CPT-11) as second-line chemotherapy after 5FU failure. CPT-11 F205, F220, F221 and V222 study groups
G Freyer, P Rougier, R Bugat, et al.
Progres En Urologie : Journal De L'Association Francaise D'Urologie Et De La Societe Francaise D'Urologie
|
February 4, 2014
[CCAFU Recommendations 2013: Penile cancer]
J Rigaud, C Avancès, P Camparo, et al.
European Journal of Cancer & Clinical Oncology
|
March 1, 1989
Relationship of histological subtypes to prognosis in early stage Hodgkin's disease: a review of 312 cases in a controlled clinical trial. The Groupe Pierre et Marie Curie
S Culine, M Henry-Amar, J Diebold, et al.
Cancer Chemotherapy and Pharmacology
|
December 29, 2000
Population pharmacokinetics of topotecan: intraindividual variability in total drug
A Montazeri, M Boucaud, F Lokiec, et al.
Prostate Cancer and Prostatic Diseases
|
November 26, 2009
Pilot trial of adjuvant paclitaxel plus androgen deprivation for patients with high-risk prostate cancer after radical prostatectomy: results on toxicity, side effects and quality-of-life
G Ploussard, B Paule, L Salomon, et al.
Cancer
|
March 26, 1999
Treatment outcome of patients with brain metastases from malignant germ cell tumors
S D Fosså, C Bokemeyer, A Gerl, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
March 6, 2014
Combining gemcitabine, cisplatin, and ifosfamide (GIP) is active in patients with relapsed metastatic germ-cell tumors (GCT): a prospective multicenter GETUG phase II trial
K Fizazi, G Gravis, A Flechon, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
September 19, 2024
Basal/squamous and mixed subtype bladder cancers present poor outcomes after neoadjuvant chemotherapy in the VESPER trial
C S Groeneveld, C Pfister, S Culine, et al.
Anti-Cancer Drugs
|
August 13, 2002
Effects of impaired renal function on the pharmacokinetics and toxicity of i.v. ZD9331, a novel non-polyglutamated thymidylate synthase inhibitor, in adult patients with solid tumors
Maja J A de Jonge, B Glimelius, Jaap Verweij, et al.
Page
of 19
Search research articles
Search
Showing results (151-160 of 185) with videos related to
Sort By:
Page
of 19
Progres En Urologie : Journal De L'Association Francaise D'Urologie Et De La Societe Francaise D'Urologie
|
February 4, 2014
[CCAFU Recommendations 2013: Testicular germ cell cancer]
X Durand, J Rigaud, C Avancès, et al.
British Journal of Cancer
|
August 17, 2000
Prognostic factors for tumour response, progression-free survival and toxicity in metastatic colorectal cancer patients given irinotecan (CPT-11) as second-line chemotherapy after 5FU failure. CPT-11 F205, F220, F221 and V222 study groups
G Freyer, P Rougier, R Bugat, et al.
Progres En Urologie : Journal De L'Association Francaise D'Urologie Et De La Societe Francaise D'Urologie
|
February 4, 2014
[CCAFU Recommendations 2013: Penile cancer]
J Rigaud, C Avancès, P Camparo, et al.
European Journal of Cancer & Clinical Oncology
|
March 1, 1989
Relationship of histological subtypes to prognosis in early stage Hodgkin's disease: a review of 312 cases in a controlled clinical trial. The Groupe Pierre et Marie Curie
S Culine, M Henry-Amar, J Diebold, et al.
Cancer Chemotherapy and Pharmacology
|
December 29, 2000
Population pharmacokinetics of topotecan: intraindividual variability in total drug
A Montazeri, M Boucaud, F Lokiec, et al.
Prostate Cancer and Prostatic Diseases
|
November 26, 2009
Pilot trial of adjuvant paclitaxel plus androgen deprivation for patients with high-risk prostate cancer after radical prostatectomy: results on toxicity, side effects and quality-of-life
G Ploussard, B Paule, L Salomon, et al.
Cancer
|
March 26, 1999
Treatment outcome of patients with brain metastases from malignant germ cell tumors
S D Fosså, C Bokemeyer, A Gerl, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
March 6, 2014
Combining gemcitabine, cisplatin, and ifosfamide (GIP) is active in patients with relapsed metastatic germ-cell tumors (GCT): a prospective multicenter GETUG phase II trial
K Fizazi, G Gravis, A Flechon, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
September 19, 2024
Basal/squamous and mixed subtype bladder cancers present poor outcomes after neoadjuvant chemotherapy in the VESPER trial
C S Groeneveld, C Pfister, S Culine, et al.
Anti-Cancer Drugs
|
August 13, 2002
Effects of impaired renal function on the pharmacokinetics and toxicity of i.v. ZD9331, a novel non-polyglutamated thymidylate synthase inhibitor, in adult patients with solid tumors
Maja J A de Jonge, B Glimelius, Jaap Verweij, et al.
Page
of 19